Emtricitabine; FTC for HBV


Long-term Adefovir (Hepsera) plus Emtricitabine (Emtriva) vs Adefovir Monotherapy for Chronic Hepatitis - 4/18/08

HAART Regimens Containing Tenofovir Plus Lamivudine or Emtricitabine Work Best for HIV-HBV Coinfected Patients  - 5/01/07

Outcomes in HIV-HBV Coinfected Patients Treated with Drugs Active Against Both Viruses 10/17/06

Antiviral Response and Resistance Surveillance for HBeAg-negative Patients in a Study Evaluating Emtricitabine Plus Clevudine versus Emtricitabine Monotherapy - 11/21/05

Once Daily Emtricitabine Produces a Reduction in Inflammation and Fibrosis in Patients with Chronic Hepatitis B - 11/24/04

Emtricitabine Shows Potent Activity When Administered Once Daily for Treatment of Chronic Hepatitis B - 11/08/04

Response Among HBeAg Positive Patients with Chronic HBV Receiving Emtricitabine 200 mg Once Daily for 1 Year Is Not Significantly Different Based on HBV Genotype at Baseline - 11/08/04

Correlation Between Genotype and Antiviral Response to Emtricitabine 200 mg Once Daily Among HBeAg-negative Chronic HBV Patients - 11/08/04

Comparison of Adefovir Dipivoxil Plus Emtricitabine Combination Therapy vs Adefovir Alone in HBeAg(+) Chronic Hepatitis B 11/01/04

Emtricitabine (FTC), FDA-approved for HIV, Also Is Active Against Chronic Hepatitis B 01/09/04